The following describes the 2006 health services research activities of the Royal Women's Hospital. This page is under development.
|
Pharmacy
|
The Pharmacy at the Women’s has participated in all research projects involving a drug or therapeutic agent.
|
The majority of our research activities are in assisting the investigators by managing the drug accountability records, randomisation preparation and maintaining dispensing records. Our role as the third person in research is vital to maintain the “double-blind” design of many projects.
Our goal for research is:
|
- to provide evidence based positive outcomes in the usage of therapeutic agents (dose findings in new and extended indications and to monitor adverse effects)
- to consistently strive to provide a quality pharmacy service that impacts on a valued outcome
|
|
The research projects that pharmacy had some involvement in 2006 are:
|
- CAP study (Caffeine for Apnoea of Prematurity)
- INIS (International Neonatal Immunotherapy Study)
- lessMAS study (tracheal lavage with exogenous surfactant in meconium aspirated syndrome)
- OVATURE study ( OVArian TUmour REsponse)
- Implanon study (multi-centred, randomized double blind placebo controlled study - control of menstrual bleeding in women using Implanon)
- Gestational diabetes : treatment with metformin compared with insulin
- GOG #182 – randomised trial in patients with epithelial ovarian or primary peritoneal carcinoma
- Phenoxodiol Study (phenoxodiol as a chemo-sensitising agent)
- Solabegron study – in women with overactive bladder
- PROGRESS (PROGesterone after previous preterm birth for preventing neonatal RESpiratory distress Syndrome)
- TIPPS study (Thrombophilia In Pregnancy Prophylaxis Study)
|
|
Pharmacy also performs ongoing drug usage evaluation and audits of selected drugs as quality assurance projects.
Outputs: the findings are presented at the annual conference organised by the Society of Hospital Pharmacists of Australia.
|
